[Antilymphocyte globulin combining with cyclosporine A in the treatment of severe aplastic anemia]. 1999

Y Zheng, and Y Chu, and Z Shao
Institute of Hematology and Blood Diseases Hospital, CAMS, PUMC, Tianjin 300020.

OBJECTIVE To explore more effective regimen for severe aplastic anemia (SAA). METHODS A prospective, randomized clinical trial was conducted to determine whether the outcome of SAA patients treated with the combination of antilymphocyte globulin(ALG) and cyclosporine A(CsA) (intensive immunosuppressive therapy, IIST) was better than that with ALG alone (non-intensive immunosuppressive therapy, NIIST). RESULTS The response rate of IIST group(83.7%) was significantly higher than that of NIIST group(57.6%), with a lower risk of early mortality and a shorter time to red cell transfusion independence. Furthermore, the recovery of bone marrow BFU-E and CFU-GM of the responding patients was more complete in IIST group than in NIIST group. CONCLUSIONS The treatment outcome was better with IIST than with NIIST for SAA.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Y Zheng, and Y Chu, and Z Shao
April 1986, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Y Zheng, and Y Chu, and Z Shao
April 1988, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Y Zheng, and Y Chu, and Z Shao
September 1978, Experimental hematology,
Y Zheng, and Y Chu, and Z Shao
July 2016, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Y Zheng, and Y Chu, and Z Shao
January 1997, Terapevticheskii arkhiv,
Y Zheng, and Y Chu, and Z Shao
May 1988, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Y Zheng, and Y Chu, and Z Shao
January 1993, Medicinski pregled,
Y Zheng, and Y Chu, and Z Shao
January 1984, Progress in clinical and biological research,
Copied contents to your clipboard!